Beyond the incidence of these mutations in early and advanced ovarian cancers, there is a significant amount of evidence indicating that increased stability of missense p53 mutant proteins and subsequent accumulation in the nucleus leads to various transcriptional and biological consequences over and above what is seen when the protein is absent (as is the case with most chain terminating mutations) [26-28]. Here, TP53 is linked to ovarian cancer.